Reducing the burden of glandular carcinomas of the uterine cervix - 22/08/11
Reprints: Bradley J. Monk, MD, Associate Professor of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Building 56 Room 262, 101 The City Dr, Orange, CA 92868Résumé |
Widespread use of the Papanicolaou test for the screening of cervical cancers has lead to a significant decline in overall incidence and mortality rates over the past 3 decades. When different histologic types of cervical cancers are considered and trends are reexamined, it becomes apparent that observed declines are reflective of squamous cell carcinomas predominantly; the rates for adenocarcinomas continue to rise. This rise in incidence may be due to the greater difficulty in screening for glandular precursor lesions that often arise high within the endocervical canal. Reducing the incidence and mortality rates that are associated with adenocarcinomas can be accomplished by using improved screening techniques and large-scale implementation of cervical cancer vaccines that target the predominant oncogenic human papillomavirus types that are associated with adenocarcinoma.
Le texte complet de cet article est disponible en PDF.Key words : cervical adenocarcinoma, cervical cancer, cervical screening, HPV, vaccine
Plan
Vol 197 - N° 6
P. 566-571 - décembre 2007 Retour au numéro
Article précédent
- Combination therapy for treatment of osteoporosis: A review
- JoAnn V. Pinkerton, Alan C. Dalkin
- The identification, management, and prevention of conflict with faculty and fellows: A practical ethical guide for department chairs and division chiefs
- Frank A. Chervenak, Laurence B. McCullough
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?